211 related articles for article (PubMed ID: 27314817)
1. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
[TBL] [Abstract][Full Text] [Related]
2. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
3. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
Kobayashi M; Tojo A
Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
[TBL] [Abstract][Full Text] [Related]
4. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
[TBL] [Abstract][Full Text] [Related]
5. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
8. Genomic Alterations in Langerhans Cell Histiocytosis.
Rollins BJ
Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
[TBL] [Abstract][Full Text] [Related]
9. Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is a Neoplastic Process: Clinicopathologic and Molecular Study of 7 Cases.
Agaimy A; Bonert M; Naqvi A; Wang C; Trpkov K; Dettmar P; Wintzer HO; Stoehr R; Hes O; Williamson SR; Gibson IW; Hartmann A
Am J Surg Pathol; 2020 Dec; 44(12):1658-1665. PubMed ID: 32910018
[TBL] [Abstract][Full Text] [Related]
10. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
Jouenne F; Benattia A; Tazi A
Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
[TBL] [Abstract][Full Text] [Related]
12. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.
Zarnegar S; Durham BH; Khattar P; Shukla NN; Benayed R; Lacouture ME; Lavi E; Lyden DC; Diamond EL; Dunkel IJ; Abdel-Wahab O
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748614
[TBL] [Abstract][Full Text] [Related]
13. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
15. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
16. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
17. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.
Bahabri A; Abla O
Expert Rev Hematol; 2024 Jun; 17(6):223-231. PubMed ID: 38721670
[TBL] [Abstract][Full Text] [Related]
18. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Satoh T; Smith A; Sarde A; Lu HC; Mian S; Trouillet C; Mufti G; Emile JF; Fraternali F; Donadieu J; Geissmann F
PLoS One; 2012; 7(4):e33891. PubMed ID: 22506009
[TBL] [Abstract][Full Text] [Related]
19.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
20. Langerhans cell histiocytosis: Version 2021.
Gulati N; Allen CE
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):15-23. PubMed ID: 34105821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
